BMO Capital Markets Reiterates “Buy” Rating for Merck & Company, Inc. (MRK)

Merck & Company, Inc. (NYSE:MRK)‘s stock had its “buy” rating reaffirmed by research analysts at BMO Capital Markets in a research report issued to clients and investors on Friday, September 8th. They currently have a $72.00 price objective on the stock. BMO Capital Markets’ target price would suggest a potential upside of 8.83% from the company’s current price.

Several other research firms have also recently commented on MRK. Jefferies Group LLC reaffirmed a “sell” rating and issued a $52.00 target price on shares of Merck & in a research report on Sunday, August 20th. J P Morgan Chase & Co raised their target price on shares of Merck & from $74.00 to $76.00 and gave the stock an “overweight” rating in a research report on Thursday, May 11th. Credit Suisse Group dropped their target price on shares of Merck & from $75.00 to $74.00 and set an “outperform” rating for the company in a research report on Wednesday, August 30th. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Vetr raised shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 target price for the company in a research report on Monday, May 15th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $70.00.

Shares of Merck & (NYSE MRK) traded up 0.06% during trading on Friday, reaching $66.16. The company had a trading volume of 14,685,767 shares. The company has a market cap of $180.44 billion, a price-to-earnings ratio of 35.82 and a beta of 0.81. The firm has a 50 day moving average price of $63.41 and a 200 day moving average price of $63.72. Merck & has a 12 month low of $58.29 and a 12 month high of $66.80.

Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. During the same quarter in the prior year, the company earned $0.93 EPS. The firm’s revenue was up .9% on a year-over-year basis. Analysts predict that Merck & will post $3.87 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “BMO Capital Markets Reiterates “Buy” Rating for Merck & Company, Inc. (MRK)” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.truebluetribune.com/2017/09/16/merck-s-mrk-buy-rating-reaffirmed-at-bmo-capital-markets.html.

Several institutional investors and hedge funds have recently bought and sold shares of MRK. Stock Yards Bank & Trust Co. boosted its holdings in shares of Merck & by 7.5% in the first quarter. Stock Yards Bank & Trust Co. now owns 53,798 shares of the company’s stock worth $3,418,000 after buying an additional 3,765 shares during the last quarter. First National Bank of Mount Dora Trust Investment Services boosted its holdings in shares of Merck & by 23.9% in the first quarter. First National Bank of Mount Dora Trust Investment Services now owns 66,505 shares of the company’s stock worth $4,226,000 after buying an additional 12,840 shares during the last quarter. Forte Capital LLC ADV boosted its holdings in shares of Merck & by 5.6% in the first quarter. Forte Capital LLC ADV now owns 21,424 shares of the company’s stock worth $1,361,000 after buying an additional 1,130 shares during the last quarter. GW&K Investment Management LLC boosted its holdings in shares of Merck & by 4.7% in the first quarter. GW&K Investment Management LLC now owns 408,948 shares of the company’s stock worth $25,985,000 after buying an additional 18,340 shares during the last quarter. Finally, Gulf International Bank UK Ltd lifted its holdings in Merck & by 1.9% during the first quarter. Gulf International Bank UK Ltd now owns 861,540 shares of the company’s stock valued at $54,742,000 after purchasing an additional 15,700 shares in the last quarter. 73.02% of the stock is currently owned by institutional investors.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Company Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

ten − seven =